The Combination of Low Skeletal Muscle Mass and High Tumor Interleukin-6 Associates with Decreased Survival in Clear Cell Renal Cell Carcinoma

被引:10
作者
Kays, Joshua K. [1 ]
Koniaris, Leonidas G. [1 ,2 ,3 ,4 ]
Cooper, Caleb A. [1 ]
Pili, Roberto [2 ,5 ]
Jiang, Guanglong [3 ]
Liu, Yunlong [2 ,3 ,6 ]
Zimmers, Teresa A. [1 ,2 ,3 ,4 ,7 ]
机构
[1] IU Sch Med, Dept Surg, Indianapolis, IN 46202 USA
[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46202 USA
[3] Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA
[4] Indiana Univ Purdue Univ Indianapolis, Ctr Cachexia Res Innovat & Therapy, Indianapolis, IN 46202 USA
[5] IU Sch Med, Dept Med, Indianapolis, IN 46202 USA
[6] IU Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA
[7] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA
基金
美国国家卫生研究院;
关键词
cachexia; body composition; kidney cancer; renal cancer; renal cell carcinoma; cytokines; muscle wasting; mortality; prognosis; risk stratification; NECROSIS-FACTOR-ALPHA; ADIPOSE-TISSUE; CANCER CACHEXIA; PROGNOSIS; INDEX; SYMPTOMS; ADIPOKINES; SARCOPENIA; RELEASE; OBESITY;
D O I
10.3390/cancers12061605
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clear cell renal carcinoma (ccRCC) is frequently associated with cachexia which is itself associated with decreased survival and quality of life. We examined relationships among body phenotype, tumor gene expression, and survival. Demographic, clinical, computed tomography (CT) scans and tumor RNASeq for 217 ccRCC patients were acquired from the Cancer Imaging Archive and The Cancer Genome Atlas (TCGA). Skeletal muscle and fat masses measured from CT scans and tumor cytokine gene expression were compared with survival by univariate and multivariate analysis. Patients in the lowest skeletal muscle mass (SKM) quartile had significantly shorter overall survival versus the top three SKM quartiles. Patients who fell into the lowest quartiles for visceral adipose mass (VAT) and subcutaneous adipose mass (SCAT) also demonstrated significantly shorter overall survival. Multiple tumor cytokines correlated with mortality, most strongly interleukin-6 (IL-6); high IL-6 expression was associated with significantly decreased survival. The combination of low SKM/high IL-6 was associated with significantly lower overall survival compared to high SKM/low IL-6 expression (26.1 months vs. not reached;p< 0.001) and an increased risk of mortality (HR = 5.95; 95% CI = 2.86-12.38). In conclusion, tumor cytokine expression, body composition, and survival are closely related, with low SKM/high IL-6 expression portending worse prognosis in ccRCC.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 49 条
  • [1] Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma
    Antoun, S.
    Baracos, V. E.
    Birdsell, L.
    Escudier, B.
    Sawyer, M. B.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (08) : 1594 - 1598
  • [2] Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies
    Antoun, Sami
    Lanoy, Emilie
    Iacovelli, Roberto
    Albiges-Sauvin, Laurence
    Loriot, Yohann
    Merad-Taoufik, Mansouriah
    Fizazi, Karim
    di Palma, Mario
    Baracos, Vickie E.
    Escudier, Bernard
    [J]. CANCER, 2013, 119 (18) : 3377 - 3384
  • [3] Cancer cachexia, mechanism and treatment
    Aoyagi, Tomoyoshi
    Terracina, Krista P.
    Raza, Ali
    Matsubara, Hisahiro
    Takabe, Kazuaki
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 7 (04) : 17 - 29
  • [4] Argiles JM, 1999, MED RES REV, V19, P223, DOI 10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO
  • [5] 2-N
  • [6] Pitfalls in defining and quantifying cachexia
    Baracos, Vickie E.
    [J]. JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2011, 2 (02) : 71 - 73
  • [7] Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6
    Belizario, Jose E.
    Fontes-Oliveira, Cibely C.
    Borges, Janaina Padua
    Kashiabara, Janete Akemi
    Vannier, Edouard
    [J]. SPRINGERPLUS, 2016, 5
  • [8] Blay JY, 1997, INT J CANCER, V72, P424, DOI 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.3.CO
  • [9] 2-N
  • [10] BLAY JY, 1992, CANCER RES, V52, P3317